In this webinar, we were joined by Dr. Felix Beaudry, PhD, a lead Genome Scientist of the LeGresley Biliary Registry. The LeGresley Biliary Registry is a research program at the Toronto General Hospital focused on improving our understanding and treatment of bile duct cancers. Dr. Beaudry is also a Scientific Associate at the Ontario institute for Cancer Research and a post-doctoral researcher at the Toronto General Hospital. 

 

During the session, he discussed basic research that identified two main subtypes of cholangiocarcinoma, each with unique molecular characteristics and potential implications for patient care. He will explored the genetic patterns of bile duct cancers linked to primary sclerosing cholangitis, an inflammatory disease that affects the bile ducts. 

 

On the clinical side, he explained what a molecular tumor board is, why it is used, and how it helps guide real‑world treatment decisions. Finally, he described an approach to biomarker reporting and the steps taken to ensure these reports are clear, useful, and meaningful for both patients and oncologists.